Neurophet to showcase AI-powered multiple sclerosis imaging solution at ACTRIMS forum 2025

Neurophet, a local artificial intelligence (AI)-powered medical imaging solution company, said it will participate in the 10th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025, which is set to take place from Feb. 27 to March 1 in Florida, the U.S.

ACTRIMS Forum 2025 serves as a leading academic platform for discussing the latest advancements in MS treatment and research. The event will bring together researchers and healthcare professionals from around the world to explore innovative solutions and effective treatment approaches for multiple sclerosis (MS).

MS is a chronic autoimmune disease of the central nervous system, primarily affecting young adults between the ages of 20 and 40, with a higher prevalence among women. The condition is most commonly found in North American and European Caucasians, while its occurrence among Asian and African populations is relatively lower.

Since MS is characterized by cycles of relapse and remission, patients frequently undergo brain MRI scans to monitor lesion recurrence and receive immediate treatment during acute flare-ups.

Even during remission, patients require periodic MRI scans—at least biannually or annually—to evaluate the effectiveness of their long-term treatment plans.

At this year's forum, Neurophet will unveil its MS imaging analysis software, Neurophet AQUA MS, through an independent booth for the first time.

Neurophet AQUA MS is a specialized software integrated into Neurophet AQUA, the company’s AI-driven brain neurodegeneration imaging analysis platform. It is designed to analyze brain images of MS patients, providing quantitative assessments of lesions, such as lesion count, volume, and progression over time, and structural changes.

A key advantage of Neurophet AQUA MS is its ability to conduct precise structural analysis and disease progression tracking using only T2-FLAIR imaging. This eliminates the need for additional MRI scans such as T1 imaging, which are costly and time-consuming. By reducing the frequency of MRI scans, the software helps lower financial burdens for patients.

The product received 510(k) clearance from the U.S. FDA in October 2024.

“By participating in ACTRIMS Forum 2025, we aim to enhance the global competitiveness and business scalability of Neurophet AQUA MS,” Neurophet Co-CEO Been Jun-kil said. “The North American market has a large MS patient population and a strong network of specialized medical professionals, making it a strategic priority for our global expansion.”